881392-57-0

Basic information

• Product Name: C₄₁H₅₃BrN₄O₁₄Si
• Synonyms: C₄₁H₅₃BrN₄O₁₄Si
• CAS NO: 881392-57-0
• Molecular Weight: 933.88
• Mol File: 881392-57-0.mol

Chemical Properties

• CAS DataBase Reference: C₄₁H₅₃BrN₄O₁₄Si(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₁H₅₃BrN₄O₁₄Si(881392-57-0)
• EPA Substance Registry System: C₄₁H₅₃BrN₄O₁₄Si(881392-57-0)

Safety Data

• Hazardous Substances Data: 881392-57-0(Hazardous Substances Data)

Upstream product

• 199393-34-5 [(R)-1-(3,5-Bis-benzyloxy-4-methoxy-phenyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester 
• 192328-48-6 (R)-Amino-(3-bromo-4-methoxy-phenyl)-acetic acid methyl ester 
• 881392-52-5 (R)-{[(R)-2-(3,5-Bis-benzyloxy-4-methoxy-phenyl)-2-tert-butoxycarbonylamino-ethyl]-methoxycarbonyl-amino}-(3-bromo-4-methoxy-phenyl)-acetic acid methyl ester 
• 881392-50-3 (R)-[(R)-2-(3,5-Bis-benzyloxy-4-methoxy-phenyl)-2-tert-butoxycarbonylamino-ethylamino]-(3-bromo-4-methoxy-phenyl)-acetic acid methyl ester 
• 881392-54-7 (R)-(3-Bromo-4-methoxy-phenyl)-{[(R)-2-tert-butoxycarbonylamino-2-(3,5-dihydroxy-4-methoxy-phenyl)-ethyl]-methoxycarbonyl-amino}-acetic acid 
• 881392-53-6 (R)-(3-Bromo-4-methoxy-phenyl)-{[(R)-2-tert-butoxycarbonylamino-2-(3,5-dihydroxy-4-methoxy-phenyl)-ethyl]-methoxycarbonyl-amino}-acetic acid methyl ester 
• 881392-49-0 [1-(3,5-bis-benzyloxy-4-methoxy-phenyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 881392-56-9 (2S,3R)-2-((R)-2-(3-Bromo-4-methoxy-phenyl)-2-{[(R)-2-tert-butoxycarbonylamino-2-(3,5-dihydroxy-4-methoxy-phenyl)-ethyl]-methoxycarbonyl-amino}-acetylamino)-3-(tert-butyl-dimethyl-silanyloxy)-3-(4-fluoro-3-nitro-phenyl)-propionic acid methyl ester 

Downstream Products

• 882184-16-9 C₄₁H₅₅BrN₄O₁₂Si 
• 881392-60-5 C₅₇H₆₇ClN₄O₁₉ 
• 881392-62-7 C₄₈H₅₉ClN₄O₁₇ 
• 881392-61-6 C₄₉H₆₁ClN₄O₁₇ 
• 881392-58-1 C₄₁H₅₃BrClN₃O₁₂Si 

Relevant articles and documents

[PSI[CH2NH]PG4] glycopeptide antibiotic analogs

[ψ[CH2NH]PG4] glycopeptide antibiotic analogs are reengineered forms of glycopeptides that exhibit antimicrobial activity against both wild type and glycopeptide antibiotic resistant strains of microorganisms. For example, [ψ[CH

Total synthesis and evaluation of [Ψ[CH2NH]Tpg 4]vancomycin aglycon: Reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding

An effective synthesis of [Ψ[CH2NH]Tpg4] vancomycin aglycon (5) is detailed in which the residue 4 amide carbonyl of vancomycin aglycon has been replaced with a methylene. This removal of a single atom was conducted to enhance bindin